Randomized Phase II Trial Comparing New Treatments to Standard Therapy in Adults with Relapsed or Refractory Follicular Lymphoma

What this Trial Is About

Researchers are investigating new treatments for patients with relapsed or refractory follicular lymphoma, aiming to find better options than the current standard therapies. This Phase II trial compares experimental therapies to standard treatments chosen by doctors before the trial. The study focuses on how patients respond to treatment, measured by PET scans after 24 weeks, to identify therapies that may improve outcomes. Patients will be randomly assigned to receive either an experimental treatment or one of five standard therapy options, such as RCHOP or bendamustine with rituximab. In the first treatment round, patients may receive epcoritamab by weekly injection combined with oral lenalidomide in 28-day cycles, up to 12 cycles. Subsequent rounds will test other new treatments, with patients more likely to receive the experimental option. The trial plans to enroll 284 patients and follow them for up to 10 years. Participants will undergo assessments including PET-CT scans, blood tests, and quality of life questionnaires before and during treatment. Researchers will track treatment responses, survival, adverse effects, and quality of life over the study period. After treatment, patients will be followed yearly to monitor long-term outcomes and any new treatments needed, with total participation lasting up to a decade.

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy